반응형
구분 보고서(영문)
제약/바이오/임상시험
(6건)		 Venture Capital Investment Trends In Pharma - Q3 2024
M&A Trends in Pharma - Q3 2024
Results of Phase I Trial Shed Positive Light on UNI-494 for Acute Kidney Injury
Q3 2024 CRO Activity and Intel Report
Unresolved Clawback Issues Obstruct Greece’s Potential Pharmaceutical Framework Agreement
Oral GLP-1 Receptor Agonist Rybelsus Reduces Risk of Cardiovascular Events in Type 2 Diabetes Patients
컨퍼런스/심포지엄/학회/기타
(12건)		 EADV 2024: Atopic Dermatitis Observations
AAO 2024: Rezolute’s RZ-402 Shows Promising Phase IIa Results in DME Patients
AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs Vision in RP Patients
AAO 2024: EyePoint’s EYP-1901 Proves Non-Inferiority to Aflibercept in DAVIO 2 Trial
IDWeek 2024: Novel Antimicrobials Poised to Make a Difference
AAO 2024: Brepocitinib Achieves Treatment Failure Reductions in NEPTUNE
IDWeek 2024: Moderna’s Norovirus Vaccine mRNA-1403 Shows Potential in Phase I/II Trial
AAO 2024: Neurodegeneration Marker Apolipoprotein E is Elevated in the Serum of Patients with Glaucoma
AAO 2024: Phase II Study on the Safety of Intravitreal NT-501 Encapsulated Cell Therapy Implantation for Glaucoma Treatment
AAO 2024: NMA Reveals that Vabysmo Achieves Superior CST Improvement Over Eylea HD
IDWeek 2024: Highlights on the Detection and Prevention of NTM Outbreaks
EADV 2024: Psoriasis and Hidradenitis Suppurativa Observations
질환별
(6건)		 COPD Market Expected to Grow to $30.8 Billion in the 7MM by 2033
Pertussis Transmission Reaches Pre-Pandemic Levels in US
Opioid Addiction: Opportunity Assessment and Forecast
Opioid Addiction Market to Reach $2.4 Billion Across 8MM by 2033
Sepsis Deaths Are Still High, with 50% Mortality Within Two Years
Bladder Cancer: Epidemiology Forecast to 2033

 

 

반응형
저작자표시

'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글

해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 11.22. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 11.08. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 10.11. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.27. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.13. (금)  (0) 2024.09.15
반응형
구분 보고서(영문)
제약/바이오/임상시험
(8건)		 US’s First Self-Administered Flu Vaccine Could Increase Accessibility and Uptake
Sanofi/Regeneron’s Dupixent Set to Dominate COPD Biologics Market Following FDA Approval
Emerging Market Outsourcing Report – Q3 2024
Asia-Pacific Dominates For Endometriosis Trials
Keytruda and Opdivo: A Decade Review
Crucial Drug Shortages Initiate Call for Action to Include Pregnant Women in Clinical Trials
A Schizophrenia Win for BMS’s Cobenfy, But Challenges Lie Ahead
Bio/Pharmaceutical Outsourcing Report, September 2024
컨퍼런스/심포지엄/학회/기타 (2건) ERS 2024 Congress: The Future of the COPD Landscape
Global Leaders Set Targets to Combat AMR at UN High-Level Meeting
질환별
(9건)		 Glycogen Storage Disorders: Competitive Landscape
Multiple System Atrophy: Competitive Landscape
Physicians Highlight Need for Improved Non-Opioid Treatments for Opioid Use Disorder
Neffy Nasal Spray: A Game Changer for Asthma Patients and Epinephrine Delivery?
Gonorrhea: Competitive Landscape
HER2+ Breast cancer: Eight-Market Drug Forecast
Sepsis: Epidemiology Forecast to 2033
Lebrikizumab, Tralokinumab, and Dupilumab to Compete in Atopic Dermatitis
Pediatric Type 2 Diabetes Faces Significant Underdiagnosis in China
반응형
저작자표시

'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글

해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 11.08. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 10.25. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.27. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.13. (금)  (0) 2024.09.15
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 8.30. (금)  (0) 2024.09.15
반응형

 

구분 보고서(영문)
제약/바이오/임상시험
(6건)		 Imfinzi Joins Checkpoint Inhibitor Battle in the Perioperative NSCLC Space
Enhertu Wins FDA Breakthrough Therapy Designation in HER2-Low/Ultralow Breast Cancer
Keytruda Beaten by Summit’s Bispecific in NSCLC
As GSK Discontinues HSV Vaccine, Opportunities Remain for Moderna and BioNTech
FDA Hits Ozempic and Mounjaro Counterfeit Compounders with Warning Letters
Biosecure Act Passes US House, Lawmakers Allege US Companies Involved in Unethical Chinese Trials
컨퍼런스/
심포지엄/
학회/기타
 (11건)		 ESMO 2024: IMbrave050 Study Results Fade the Hope of Tecentriq + Avastin as First Adjuvant Therapy for HCC
EASD 2024: GLP-1R Agonists Treatment Improves Glucose Control and Reduces Bodyweight in Type 1 Diabetes Patients
ESMO 2024: Enhertu to Eclipse the Standard of Care in HER2+ Breast Cancer with Brain Metastases
ESMO 2024: Anlotinib and Penpulimab, to the Moon and Beyond for Advanced HCC?
ESMO 2024: Emerging TROP2-Directed ADCs Provide Promise in Recurrent Endometrial and Ovarian Cancers
ESMO 2024: TIGIT Race Tightens with First Look at GSK & iTeos’s TIGIT in NSCLC
ESMO 2024: AstraZeneca’s Imfinzi to Change Perioperative Bladder Cancer Setting
ESMO 2024: Eli Lilly Brings the Competition to Novartis With New Results in mCRPC
ESMO 2024: Pembrolizumab is KEY to First-Line Treatment of HER2+ mGEJ Adenocarcinoma
ESMO 2024: Keytruda Keys in on Survival in KEYNOTE-522 High-Risk Early TNBC Patients
European Society for Medical Oncology (ESMO) 2024 Highlights
질환별
(3건)		 World Sepsis Day 2024: Improved Trial Design and Targeted Drugs Remain Unmet Needs
Uncontrolled Antimicrobial Use to Cause Rise in Deaths Due to Superbugs
COPD: Seven -Market Drug Forecast and Market Analysis
반응형
저작자표시

'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글

해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 10.25. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 10.11. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.13. (금)  (0) 2024.09.15
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 8.30. (금)  (0) 2024.09.15
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 8.14. (수)  (0) 2024.09.15
반응형

 

구분 보고서(영문)
제약/바이오/
임상시험
(3건)		 Bio/Pharmaceutical Outsourcing Report, August 2024
Migraine Market Expected to Reach $16.4 Billion Across 7MM by 2033
Emerging Microbiome Market—Unlocking New Frontiers
컨퍼런스/
심포지엄/
학회/기타
(17건)		 ESC 2024: Obicetrapib - A Promising Breakthrough for Dyslipidemia Treatment
ESC 2024: SELECT Trial Provides Promising Results for the Treatment of Obesity-Related HFpEF with Semaglutide 2.4mg
ESC 2024: Additional Analysis of FLOW Trial Highlights That CKD Patients Could Positively Benefit From Ozempic
ESC 2024: Retatrutide Improves Lipid and Cardiovascular Risk Profile in Phase II Trial
ESC 2024: Study Highlights Novartis’ Potential to Differentiate in HF Space
ESC 2024: Sacubitril/Valsartan Continues to Impress in HF
ESC 2024: FINEARTS-HF Trial Sheds Positive Light on Kerendia for HFmrEF/HFpEF
ESC 2024: Results From CATHEDRAL-HF Trial Has the Potential to Reduce Polypharmacy
ESC 2024: GLP-1RAs Lower Cardiovascular Risk in Meta-Analysis of 32,884 Patients
EASD 2024: Survodutide Shows Promise in Overweight, Obesity, and MASH
EASD 2024: Novel Insights into Maternal Protection in Type 1 Diabetes
EASD 2024: Bayer’s Kerendia Continues to Impress with Pooled Analysis
EASD 2024: Cardiovascular and Inflammatory Markers Decrease after Treatment with Oral GLP-1R Agonist Orforglipron
EASD 2024: Mazdutide Improves Cardiometabolic Function in Patients with Obesity or Overweight
EASD 2024: New Developments in Presymptomatic Type 1 Diabetes Screening
EASD 2024: Are Tetra-Agonists the Future of Metabolic Diseases Treatment?
EASD 2024: A COMBINEd Approach for Better Diabetes Management
질환별
(5건)		 NICE Approves New Osteoporosis Treatment for High-Risk Patients in the UK
Sickle Cell in September: Spreading Awareness and Supporting Solutions
Rising ADHD Diagnoses in 7MM Linked to Standardized Screening Tools and Guidelines
Uterine Leiomyoma: Competitive Landscape 
Dysmenorrhea: Competitive Landscape
반응형
저작자표시

'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글

해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 10.11. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 9.27. (금)  (0) 2025.01.06
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 8.30. (금)  (0) 2024.09.15
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 8.14. (수)  (0) 2024.09.15
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 7.5. (금)  (0) 2024.09.15

+ Recent posts

티스토리툴바